A Single 60 mg Dose of Denosumab Might Improve Hepatic Insulin Sensitivity in Postmenopausal Nondiabetic Severe Osteoporotic Women
Background. The RANKL/RANK/OPG signaling pathway is crucial for the regulation of osteoclast activity and bone resorption being activated in osteoporosis. The pathway has been also suggested to influence glucose metabolism as observed in chronic low inflammation. Aim. To test whether systemic blocka...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2015-01-01
|
| Series: | International Journal of Endocrinology |
| Online Access: | http://dx.doi.org/10.1155/2015/352858 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832561180990767104 |
|---|---|
| author | Elena Passeri Stefano Benedini Elena Costa Sabrina Corbetta |
| author_facet | Elena Passeri Stefano Benedini Elena Costa Sabrina Corbetta |
| author_sort | Elena Passeri |
| collection | DOAJ |
| description | Background. The RANKL/RANK/OPG signaling pathway is crucial for the regulation of osteoclast activity and bone resorption being activated in osteoporosis. The pathway has been also suggested to influence glucose metabolism as observed in chronic low inflammation. Aim. To test whether systemic blockage of RANKL by the monoclonal antibody denosumab influences glucose metabolism in osteoporotic women. Study Design.
This is a prospective study on the effect of a subcutaneously injected single 60 mg dose of denosumab in 14 postmenopausal severe osteoporotic nondiabetic women evaluated at baseline and 4 and 12 weeks after their first injection by an oral glucose tolerance test. Results. A single 60 mg dose of denosumab efficiently inhibited serum alkaline phosphatase while it did not exert any significant variation in fasting glucose, insulin, or HOMA-IR at both 4 and 12 weeks. No changes could be detected in glucose response to the glucose load, Matsuda Index, or insulinogenic index. Nonetheless, 60 mg denosumab induced a significant reduction in the hepatic insulin resistance index at 4 weeks and in HbA1c levels at 12 weeks. Conclusions. A single 60 mg dose of denosumab might positively affect hepatic insulin sensitivity though it does not induce clinical evident glucose metabolic disruption in nondiabetic patients. |
| format | Article |
| id | doaj-art-e0fca4fe0d824eeb98e87260f260babf |
| institution | Kabale University |
| issn | 1687-8337 1687-8345 |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Endocrinology |
| spelling | doaj-art-e0fca4fe0d824eeb98e87260f260babf2025-02-03T01:25:50ZengWileyInternational Journal of Endocrinology1687-83371687-83452015-01-01201510.1155/2015/352858352858A Single 60 mg Dose of Denosumab Might Improve Hepatic Insulin Sensitivity in Postmenopausal Nondiabetic Severe Osteoporotic WomenElena Passeri0Stefano Benedini1Elena Costa2Sabrina Corbetta3Endocrinology and Diabetology Unit, IRCCS Policlinico San Donato, 20097 San Donato Milanese, ItalyEndocrinology and Diabetology Unit, Department of Biomedical Sciences for Health, University of Milan, IRCCS Policlinico San Donato, 20097 San Donato Milanese, ItalyClinical Laboratory, IRCCS Policlinico San Donato, 20097 San Donato Milanese, ItalyEndocrinology and Diabetology Unit, Department of Biomedical Sciences for Health, University of Milan, IRCCS Policlinico San Donato, 20097 San Donato Milanese, ItalyBackground. The RANKL/RANK/OPG signaling pathway is crucial for the regulation of osteoclast activity and bone resorption being activated in osteoporosis. The pathway has been also suggested to influence glucose metabolism as observed in chronic low inflammation. Aim. To test whether systemic blockage of RANKL by the monoclonal antibody denosumab influences glucose metabolism in osteoporotic women. Study Design. This is a prospective study on the effect of a subcutaneously injected single 60 mg dose of denosumab in 14 postmenopausal severe osteoporotic nondiabetic women evaluated at baseline and 4 and 12 weeks after their first injection by an oral glucose tolerance test. Results. A single 60 mg dose of denosumab efficiently inhibited serum alkaline phosphatase while it did not exert any significant variation in fasting glucose, insulin, or HOMA-IR at both 4 and 12 weeks. No changes could be detected in glucose response to the glucose load, Matsuda Index, or insulinogenic index. Nonetheless, 60 mg denosumab induced a significant reduction in the hepatic insulin resistance index at 4 weeks and in HbA1c levels at 12 weeks. Conclusions. A single 60 mg dose of denosumab might positively affect hepatic insulin sensitivity though it does not induce clinical evident glucose metabolic disruption in nondiabetic patients.http://dx.doi.org/10.1155/2015/352858 |
| spellingShingle | Elena Passeri Stefano Benedini Elena Costa Sabrina Corbetta A Single 60 mg Dose of Denosumab Might Improve Hepatic Insulin Sensitivity in Postmenopausal Nondiabetic Severe Osteoporotic Women International Journal of Endocrinology |
| title | A Single 60 mg Dose of Denosumab Might Improve Hepatic Insulin Sensitivity in Postmenopausal Nondiabetic Severe Osteoporotic Women |
| title_full | A Single 60 mg Dose of Denosumab Might Improve Hepatic Insulin Sensitivity in Postmenopausal Nondiabetic Severe Osteoporotic Women |
| title_fullStr | A Single 60 mg Dose of Denosumab Might Improve Hepatic Insulin Sensitivity in Postmenopausal Nondiabetic Severe Osteoporotic Women |
| title_full_unstemmed | A Single 60 mg Dose of Denosumab Might Improve Hepatic Insulin Sensitivity in Postmenopausal Nondiabetic Severe Osteoporotic Women |
| title_short | A Single 60 mg Dose of Denosumab Might Improve Hepatic Insulin Sensitivity in Postmenopausal Nondiabetic Severe Osteoporotic Women |
| title_sort | single 60 mg dose of denosumab might improve hepatic insulin sensitivity in postmenopausal nondiabetic severe osteoporotic women |
| url | http://dx.doi.org/10.1155/2015/352858 |
| work_keys_str_mv | AT elenapasseri asingle60mgdoseofdenosumabmightimprovehepaticinsulinsensitivityinpostmenopausalnondiabeticsevereosteoporoticwomen AT stefanobenedini asingle60mgdoseofdenosumabmightimprovehepaticinsulinsensitivityinpostmenopausalnondiabeticsevereosteoporoticwomen AT elenacosta asingle60mgdoseofdenosumabmightimprovehepaticinsulinsensitivityinpostmenopausalnondiabeticsevereosteoporoticwomen AT sabrinacorbetta asingle60mgdoseofdenosumabmightimprovehepaticinsulinsensitivityinpostmenopausalnondiabeticsevereosteoporoticwomen AT elenapasseri single60mgdoseofdenosumabmightimprovehepaticinsulinsensitivityinpostmenopausalnondiabeticsevereosteoporoticwomen AT stefanobenedini single60mgdoseofdenosumabmightimprovehepaticinsulinsensitivityinpostmenopausalnondiabeticsevereosteoporoticwomen AT elenacosta single60mgdoseofdenosumabmightimprovehepaticinsulinsensitivityinpostmenopausalnondiabeticsevereosteoporoticwomen AT sabrinacorbetta single60mgdoseofdenosumabmightimprovehepaticinsulinsensitivityinpostmenopausalnondiabeticsevereosteoporoticwomen |